PRODUCT INFORMATION



Thromboxane B₂

Item No. 19030

CAS Registry No.:	54397-85-2	
Formal Name:	9α,11,15S-trihydroxythromba-5Z,13E-dien-1-oic acid	OH
Synonym:	TXB ₂	$\dot{\wedge}$ $\dot{\wedge}$ $ \dot{\wedge}$ $\dot{\wedge}$
MF:	$C_{20}H_{34}O_{6}$	COOH
FW:	370.5	
Purity:	≥98%	
Supplied as:	A crystalline solid	ОН
Storage:	-20°C	
Stability:	≥4 years	

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Thromboxane B_2 (TXB₂) is supplied as a crystalline solid. A stock solution may be made by dissolving the TXB₂ in the solvent of choice, which should be purged with an inert gas. TXB₂ is soluble in organic solvents such as ethanol, methyl acetate, DMSO, and dimethyl formamide. The solubility of TXB₂ in these solvents is approximately 100, 10, 25, and 50 mg/ml, respectively.

Further dilutions of the stock solution into aqueous buffers or isotonic saline should be made prior to performing biological experiments. Ensure that the residual amount of organic solvent is insignificant, since organic solvents may have physiological effects at low concentrations. Organic solvent-free aqueous solutions of TXB₂ can be prepared by directly dissolving the crystalline solid in aqueous buffers. The solubility of TXB₂ in PBS (pH 7.2) is approximately 100 μ g/ml. We do not recommend storing the aqueous solution for more than one day.

Description

Thromboxane B₂ (TXB₂) is a non-enzymatically derived, stable, inactive metabolite of TXA₂, which is highly unstable.¹⁻³ Serum levels of TXB₂ positively correlate with platelet COX-1 activation.^{4,5} Urinary levels of TXB₂ reflect intrarenal TXA₂ synthesis, while its metabolites, 11-dehydro TXB₂ (Item No. 19500) and 2,3-dinor TXB₂ (Item No. 19510), reflect systemic TXA₂ secretion.^{2,6,7}

References

- 1. Needleman, P., Moncada, S., Bunting, S., et al. Identification of an enzyme in platelet microsomes which generates thromboxane A₂ from prostaglandin endoperoxides. *Nature* **261(5561)**, 558-560 (1976).
- 2. Patrono, C., Ciabattoni, G., Pugliese, F., et al. Estimated rate of thromboxane secretion into the circulation of normal humans. J. Clin. Invest. 77(2), 590-594 (1986).
- Uyama, O., Matsumoto, M., Fujisawa, A., et al. Plasma concentrations of thromboxane B₂ in patients with 3. hypertension or cerebrovascular disease. Prostaglandins Med. 7(3), 199-207 (1981).
- Arantes, F.B.B., Menezes, F.R., Franci, A., et al. Influence of direct thrombin inhibitor and low molecular weight heparin on platelet function in patients with coronary artery disease: A prospective interventional trial. Adv. Ther. 37(1), 420-430 (2020).
- 5. Ferroni, P., Riondino, S., Vazzana, N., et al. Biomarkers of platelet activation in acute coronary syndromes. Thromb. Haemost. 108(6), 1109-1123 (2012).
- Lawson, J.A., Patrono, C., Ciabattoni, G., et al. Long-lived enzymatic metabolites of thromboxane B₂ in the 6. human circulation. Anal. Biochem. 155(1), 198-205 (1986).
- 7. Patrono, C., Ciabattoni, G., Patrignani, P., et al. Evidence for a renal origin of urinary thromboxane B₂ in health and disease. Adv. Prostaglandin Thromboxane Leukot. Res. 11, 493-498 (1983).

WARNING THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

uyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/15/2024

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD ANN ARBOR, MI 48108 · USA PHONE: [800] 364-9897 [734] 971-3335 FAX: [734] 971-3640 CUSTSERV@CAYMANCHEM.COM WWW.CAYMANCHEM.COM